• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Janus激酶在骨髓瘤细胞中ErbB3与干扰素-α信号复合物之间的串扰中的作用。

A role for Janus kinases in crosstalk between ErbB3 and the interferon-alpha signaling complex in myeloma cells.

作者信息

Walters Denise K, Jelinek Diane F

机构信息

Department of Immunology, Tumor Biology Program, Mayo Graduate and Medical Schools, Mayo Clinic/Foundation, Rochester, MN 55905, USA.

出版信息

Oncogene. 2004 Feb 12;23(6):1197-205. doi: 10.1038/sj.onc.1207203.

DOI:10.1038/sj.onc.1207203
PMID:14647450
Abstract

Receptor crosstalk is an emerging and recurrent theme in cytokine and growth factor signaling; however, insight into the mechanism(s) underlying these interactions remains limited. Recently, we reported that crosstalk occurs between ErbB3 and the interferon alpha (IFN-alpha) signaling complex in the myeloma cell line KAS-6/1 and that this crosstalk contributes to the regulation of cell proliferation. In this study, we examined the mechanism underlying the transactivation of ErbB3 in the IFN-alpha growth-responsive KAS-6/1 cells. The examination of IFN-alpha receptor 1 and 2 (IFNAR1 and IFNAR2) levels revealed that the KAS-6/1 cell line overexpresses IFNAR1 relative to other myeloma cell lines that are growth arrested by IFN-alpha. Subsequent investigation of Tyk2, which is constitutively associated with IFNAR1, demonstrated that Tyk2 activation is uniquely sustained in the KAS-6/1 cell line following IFN-alpha stimulation. Interestingly, silencing of Tyk2 expression via siRNA resulted in attenuation of ErbB3 transactivation. However, inhibition of Jak1 expression also decreased IFN-alpha-induced tyrosine phosphorylation of ErbB3. Finally, siRNA downregulation of Tyk2 and Jak1 was found to decrease IFN-alpha-stimulated proliferation. These findings validate our previous report of ErbB3 involvement in IFN-alpha-induced proliferation and further suggest that both Janus kinase members, Tyk2 and Jak1, play a role in the transactivation of ErbB3 in this model system.

摘要

受体间相互作用是细胞因子和生长因子信号传导中一个新出现且反复出现的主题;然而,对这些相互作用背后机制的了解仍然有限。最近,我们报道在骨髓瘤细胞系KAS-6/1中,ErbB3与干扰素α(IFN-α)信号复合物之间存在相互作用,且这种相互作用有助于调节细胞增殖。在本研究中,我们研究了IFN-α生长反应性KAS-6/1细胞中ErbB3反式激活的机制。对IFN-α受体1和2(IFNAR1和IFNAR2)水平的检测显示,与其他被IFN-α阻滞生长的骨髓瘤细胞系相比,KAS-6/1细胞系中IFNAR1过表达。随后对与IFNAR1组成性相关的Tyk2的研究表明,在IFN-α刺激后,Tyk2的激活在KAS-6/1细胞系中独特地持续存在。有趣的是,通过小干扰RNA(siRNA)沉默Tyk2表达导致ErbB3反式激活减弱。然而,抑制Jak1表达也降低了IFN-α诱导的ErbB3酪氨酸磷酸化。最后,发现通过siRNA下调Tyk2和Jak1可降低IFN-α刺激的细胞增殖。这些发现证实了我们之前关于ErbB3参与IFN-α诱导的增殖的报道,并进一步表明,在该模型系统中,Janus激酶家族成员Tyk2和Jak1在ErbB3的反式激活中均发挥作用。

相似文献

1
A role for Janus kinases in crosstalk between ErbB3 and the interferon-alpha signaling complex in myeloma cells.Janus激酶在骨髓瘤细胞中ErbB3与干扰素-α信号复合物之间的串扰中的作用。
Oncogene. 2004 Feb 12;23(6):1197-205. doi: 10.1038/sj.onc.1207203.
2
Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-alpha signaling complex.骨髓瘤细胞中ErbB3的非典型表达:ErbB3与α-干扰素信号复合体之间的相互作用
Oncogene. 2003 Jun 5;22(23):3598-607. doi: 10.1038/sj.onc.1206512.
3
Impaired alpha-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells.移行细胞癌中α-干扰素信号传导受损:5637细胞中缺乏p48表达。
Cancer Res. 2001 Mar 1;61(5):2261-6.
4
Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines.人肝癌细胞系中干扰素α受体的表达及干扰素α对其生长的抑制作用
Hepatology. 1999 Jun;29(6):1708-17. doi: 10.1002/hep.510290624.
5
Identification of residues of the IFNAR1 chain of the type I human interferon receptor critical for ligand binding and biological activity.鉴定对配体结合和生物活性至关重要的人I型干扰素受体IFNAR1链的残基。
Biochemistry. 2004 Oct 5;43(39):12498-512. doi: 10.1021/bi049111r.
6
The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha.I型干扰素受体基因的上调在5-氟尿嘧啶和α干扰素协同抗增殖作用的肝癌细胞中起关键作用。
Int J Oncol. 2006 Dec;29(6):1469-78.
7
Functional cartography of the ectodomain of the type I interferon receptor subunit ifnar1.I型干扰素受体亚基ifnar1胞外域的功能图谱
J Mol Biol. 2005 Jul 15;350(3):476-88. doi: 10.1016/j.jmb.2005.05.008.
8
Transactivation of gp130 in myeloma cells.
J Immunol. 2003 Apr 1;170(7):3717-23. doi: 10.4049/jimmunol.170.7.3717.
9
Stronger growth-inhibitory effect of interferon (IFN)-beta compared to IFN-alpha is mediated by IFN signaling pathway in hepatocellular carcinoma cells.在肝癌细胞中,与干扰素(IFN)-α相比,干扰素(IFN)-β更强的生长抑制作用是由IFN信号通路介导的。
Int J Oncol. 2007 Jan;30(1):201-8.
10
Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2.黏液瘤病毒通过阻断Janus激酶Tyk2的激活,选择性地破坏原代人成纤维细胞中的I型干扰素信号传导。
Virology. 2009 Apr 25;387(1):136-46. doi: 10.1016/j.virol.2009.02.013. Epub 2009 Feb 28.

引用本文的文献

1
Exploring the causal relationship between gut microbiota and multiple myeloma risk based on Mendelian randomization and biological annotation.基于孟德尔随机化和生物学注释探索肠道微生物群与多发性骨髓瘤风险之间的因果关系。
Front Microbiol. 2024 Feb 12;15:1310444. doi: 10.3389/fmicb.2024.1310444. eCollection 2024.
2
The Calcium-Induced Regulation in the Molecular and Transcriptional Circuitry of Human Inflammatory Response and Autoimmunity.钙诱导的人类炎症反应和自身免疫分子及转录调控机制
Front Pharmacol. 2018 Jan 8;8:962. doi: 10.3389/fphar.2017.00962. eCollection 2017.
3
Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.
靶向ErbB3:前列腺癌治疗领域的新型受体酪氨酸激酶(类药物)
Immunol Endocr Metab Agents Med Chem. 2011 Jun;11(2):131-149. doi: 10.2174/187152211795495643.
4
Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family.信号整合:理解靶向人类表皮生长因子受体(EGFR)家族疗法疗效的框架
J Clin Invest. 2008 Nov;118(11):3574-81. doi: 10.1172/JCI36049.
5
The ERBB3 receptor in cancer and cancer gene therapy.癌症中的ERBB3受体与癌症基因治疗
Cancer Gene Ther. 2008 Jul;15(7):413-48. doi: 10.1038/cgt.2008.15. Epub 2008 Apr 11.